Lin BioScience (ROCO:6696) Accounts Payable & Accrued Expense : NT$127.74 Mil (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Lin BioScience Accounts Payable & Accrued Expense?

Lin BioScience's quarterly accounts payable & accrued expense increased from Jun. 2022 (NT$22.70 Mil) to Dec. 2022 (NT$62.46 Mil) and increased from Dec. 2022 (NT$62.46 Mil) to Jun. 2023 (NT$127.74 Mil).

Lin BioScience's annual accounts payable & accrued expense increased from Dec. 2021 (NT$49.14 Mil) to Dec. 2022 (NT$62.46 Mil) and increased from Dec. 2022 (NT$62.46 Mil) to Dec. 2023 (NT$123.11 Mil).

Lin BioScience Accounts Payable & Accrued Expense Historical Data

The historical data trend for Lin BioScience's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lin BioScience Accounts Payable & Accrued Expense Chart

Lin BioScience Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

36.79

29.68

49.14

62.46

123.11

Lin BioScience Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial										49.14	22.70	62.46	127.74	123.11

Lin BioScience Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Lin BioScience (ROCO:6696) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lin BioScience Inc (ROCO:6696) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Zhongxiao East Road, 12th Floor, No. 68, Section 5, Xinyi District, Taipei City, TWN, 110

Website

https://www.linbioscience.com

Lin BioScience Inc is a drug development company. It specializes in therapies for diseases with unmet medical needs. Its novel pipeline consists of first-in-class drugs aimed at treating life-threatening or disabling diseases in oncology, ophthalmology, cardiovascular, and metabolic disease.

Lin BioScience (ROCO:6696) Headlines

No Headlines